Currently, the immune checkpoint inhibitors approved by the FDA for CRC are anti-(CTLA-4) (ipilimumab), PD-1 programmed cell death protein 1 (pembrolizumab and nivolumab), and PDL-1(atezolizumab, avelumab, and durvalumab). The gene discussed is PDCD1; the disease is colorectal carcinoma.